What is the 13F Pro Quality Score for SKYE?

13F Pro ranks Skye Bioscience, Inc. (SKYE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SKYE's current score at https://13fpro.ai/research/SKYE (free sign-up required for the full ranking).

Where does 13F Pro source SKYE data?

All Skye Bioscience, Inc. fundamentals and ownership data come directly from SEC EDGAR. Skye Bioscience, Inc. files with the SEC under CIK 1516551. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SKYE in?

Skye Bioscience, Inc. (SKYE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SKYE research updated on 13F Pro?

SKYE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Skye Bioscience, Inc.(SKYE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1516551 SKYE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SKYE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Skye Bioscience, Inc. (SKYE), a Healthcare sector company. SKYE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Skye Bioscience, Inc. reports net income of $-12.5M, free cash flow of $-8.6M. Top institutional holders of SKYE by reported 13-F value include 5AM Venture Management,, Versant Venture Management,, BAKER BROS. ADVISORS, based on the most recent SEC filings. SKYE trades on the Nasdaq exchange and files with the SEC under CIK 1516551. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SKYE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Skye Bioscience, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-12.5M

Free Cash Flow

Q1 2026

$-8.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+29.4% YoY

$-26.6MFY 2024

FY21 $-8.5MFY22 $-19.5MFY23 $-37.6MFY24 $-26.6M

Operating Income

+13.1% YoY

$-30.2MFY 2024

FY21 $-7.8MFY22 $-18.3MFY23 $-34.7MFY24 $-30.2M

EPS (Diluted)

+86.4% YoY

$-0.73FY 2024

FY21 $-0.00FY22 $-0.03FY23 $-5.37FY24 $-0.73

Total Assets

+509.4% YoY

$72.8MFY 2024

FY21 $9.9MFY22 $9.1MFY23 $11.9MFY24 $72.8M

Op. Cash Flow

-80.9% YoY

$-25.2MFY 2024

FY21 $-6.5MFY22 $-12.7MFY23 $-14.0MFY24 $-25.2M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Net Income	$-26.6M +29.4%	$-37.6M -93.2%	$-19.5M -128.6%	$-8.5M -29.9%	$-6.6M +65.8%	$-19.2M
Operating Income	$-30.2M +13.1%	$-34.7M -89.7%	$-18.3M -133.3%	$-7.8M -24.8%	$-6.3M -34.0%	$-4.7M
EPS (Diluted)	$-0.73 +86.4%	$-5.37 -16172.7%	$-0.03 -32900.0%	$-0.00 +0.0%	$-0.00 +83.3%	$-0.00
Total Assets	$72.8M +509.4%	$11.9M +31.1%	$9.1M -7.5%	$9.9M +268.9%	$2.7M +36.5%	$2.0M
Operating Cash Flow	$-25.2M -80.9%	$-14.0M -9.5%	$-12.7M -96.8%	$-6.5M -6.9%	$-6.1M -53.5%	$-3.9M

AI Insight: SKYE Financial Trends

Skye Bioscience is rapidly depleting equity—down 88% from Q2 2024 to Q1 2026—while operating losses persist and cash burn accelerates.

• Equity collapsed from $73M (Q2 2024) to $9M (Q1 2026), a loss of $64M over 8 quarters.

• Operating losses widened from $8M (Q2 2024) to $15M (Q4 2025), though slightly improved to $13M in Q1 2026.

• Operating cash burn peaked at $13M in Q3 2025; recent quarter shows $9M outflow, indicating persistent negative cash generation.

⚠ Equity now stands at $9M with no apparent revenue; solvency risk escalates if losses continue at current pace.

⚠ Net losses ranged $4M–$18M per quarter; Q1 2026 stabilized at $13M but underlying profitability remains elusive.

AI Insight: SKYE Ratio Trends

Skye Bioscience shows severe and worsening profitability deterioration, with ROE plunging from -43.4% in Q2 2024 to -161.4% in Q2 2025.

• ROE collapsed from -43.4% (Q2 2024) to -161.4% (Q2 2025), signaling accelerating net losses relative to shareholder equity.

• ROIC declined from -46.2% (Q2 2024) to -79.4% (Q1 2025), indicating deteriorating returns on invested capital over nine months.

• Data gaps in recent quarters (Q4 2025, Q1 2026) prevent assessment of latest profitability trends.

⚠ ROE worsened 18pp between Q3 2025 (-155.4%) and Q2 2025 (-161.4%); trajectory suggests continued cash burn and equity erosion.

⚠ Absence of OpMargin and NPM data prevents margin-level diagnosis; verify whether losses stem from operational or financing issues.

Get alerted when SKYE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Skye Bioscience, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SKYE

5AM Venture Management, LLC
$6.0M9,681,763 sh
Versant Venture Management, LLC
$1.2M2,007,704 sh
BAKER BROS. ADVISORS LP
$968.1K1,575,243 sh
VANGUARD CAPITAL MANAGEMENT LLC
$470.1K764,457 sh
SPHERA FUNDS MANAGEMENT LTD.
$417.3K678,928 sh
BlackRock, Inc.
$175.9K286,131 sh
GEODE CAPITAL MANAGEMENT, LLC
$170.4K277,256 sh
MILLENNIUM MANAGEMENT LLC
$158.7K258,200 sh
PLATINUM INVESTMENT MANAGEMENT LTD
$143.3K233,095 sh
VANGUARD FIDUCIARY TRUST CO
$64.1K104,229 sh

Fund	Value	Shares
5AM Venture Management, LLC	$6.0M	9,681,763
Versant Venture Management, LLC	$1.2M	2,007,704
BAKER BROS. ADVISORS LP	$968.1K	1,575,243
VANGUARD CAPITAL MANAGEMENT LLC	$470.1K	764,457
SPHERA FUNDS MANAGEMENT LTD.	$417.3K	678,928
BlackRock, Inc.	$175.9K	286,131
GEODE CAPITAL MANAGEMENT, LLC	$170.4K	277,256
MILLENNIUM MANAGEMENT LLC	$158.7K	258,200
PLATINUM INVESTMENT MANAGEMENT LTD	$143.3K	233,095
VANGUARD FIDUCIARY TRUST CO	$64.1K	104,229

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SKYE on your watchlist

Track score changes the day Skye Bioscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SKYE a good stock to buy?

13F Pro's AI-powered analysis of Skye Bioscience, Inc. (SKYE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SKYE are available on the SKYE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SKYE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SKYE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Skye Bioscience, Inc.'s investment landscape.